Women worldwide who count on Ferring Pharmaceuticals' flagship fertility drug may miss out from now into the future after the move to stop all shipments of Menopur.

The medication causes non-ovulating women to release eggs. The packaging describes how consumers going through in vitro fertilisation require daily dosages of Menopur for almost three weeks.

“Women worldwide who count on Ferring Pharmaceuticals' flagship fertility drug may miss out from now into the future after the move to stop all shipments of Menopur.“

Ferring’s injectable medication has seen “changes in the manufacturing process” for internal components “by a third-party supplier.”

Ferring’s chief science officer, Elizabeth Garner, described that they “are currently reviewing this situation and will provide updates as appropriate.”

Ferring is attempting to minimise any supply disruptions after notifying the FDA and other international agencies of the problem.

Apparently, “the safety and efficacy of the product remains unaltered. Ferring is not aware of any evidence indicating that the changes in the manufacturing process pose any risks to patients.”

However, they were unable to make a statement on when the product would possibly return to the market.

Ferrings April finance report dictated that Menopur generated total sales of over €750 million this year. Overall, at constant currency rates, Ferring reported 2021 sales of €2.16 billion, an increase of 14% compared to 2020.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.